175 related articles for article (PubMed ID: 1678995)
21. Novel plant triterpenoid drug amooranin overcomes multidrug resistance in human leukemia and colon carcinoma cell lines.
Ramachandran C; Rabi T; Fonseca HB; Melnick SJ; Escalon EA
Int J Cancer; 2003 Jul; 105(6):784-9. PubMed ID: 12767063
[TBL] [Abstract][Full Text] [Related]
22. A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport.
Lee FY; Sciandra J; Siemann DW
Biochem Pharmacol; 1989 Nov; 38(21):3697-705. PubMed ID: 2574574
[TBL] [Abstract][Full Text] [Related]
23. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells.
Dong Z; Radinsky R; Fan D; Tsan R; Bucana CD; Wilmanns C; Fidler IJ
J Natl Cancer Inst; 1994 Jun; 86(12):913-20. PubMed ID: 7910854
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of multiple drug resistance in human bladder cancer cell lines.
Shinohara N; Liebert M; Wedemeyer G; Chang JH; Grossman HB
J Urol; 1993 Aug; 150(2 Pt 1):505-9. PubMed ID: 8100862
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
Toffoli G; Corona G; Gigante M; Boiocchi M
Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
[TBL] [Abstract][Full Text] [Related]
26. Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.
Dietel M; Herzig I; Reymann A; Brandt I; Schaefer B; Bunge A; Heidebrecht HJ; Seidel A
J Cancer Res Clin Oncol; 1994; 120(5):263-71. PubMed ID: 7907333
[TBL] [Abstract][Full Text] [Related]
27. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
[TBL] [Abstract][Full Text] [Related]
28. Cellular accumulation and DNA damage induced by liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum+ ++(II) in LoVo and LoVo/PDD cells.
Han I; Nguyen T; Yang LY; Khokhar AR; Perez-Soler R
Anticancer Drugs; 1994 Feb; 5(1):64-8. PubMed ID: 8186432
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin retention and chemoresistance in human mesothelioma cell lines.
Isobe H; Wellham L; Sauerteig A; Sridhar KS; Ramachandran C; Krishan A
Int J Cancer; 1994 May; 57(4):581-5. PubMed ID: 7910154
[TBL] [Abstract][Full Text] [Related]
30. Flow cytometric analysis of multidrug-resistance-associated antigen (P-glycoprotein) and DNA ploidy in human colon cancer.
Danova M; Giordano M; Erba E; Palmeri S; Candiloro V; Riccardi A; Ucci G; Mazzini G; D'Incalci M; Ascari E
J Cancer Res Clin Oncol; 1992; 118(8):575-80. PubMed ID: 1355483
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone.
Dalton WS; Cress AE; Alberts DS; Trent JM
Cancer Res; 1988 Apr; 48(7):1882-8. PubMed ID: 2894893
[TBL] [Abstract][Full Text] [Related]
32. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells.
Kitazono M; Sumizawa T; Takebayashi Y; Chen ZS; Furukawa T; Nagayama S; Tani A; Takao S; Aikou T; Akiyama S
J Natl Cancer Inst; 1999 Oct; 91(19):1647-53. PubMed ID: 10511592
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.
Huet S; Schott B; Robert J
Br J Cancer; 1992 Apr; 65(4):538-44. PubMed ID: 1348623
[TBL] [Abstract][Full Text] [Related]
34. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari JP; Atassi G
Biochem Pharmacol; 1992 Nov; 44(9):1707-15. PubMed ID: 1360210
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of multidrug resistance in human tumour cell lines and complete reversion of cellular resistance.
Boiocchi M; Toffoli G
Eur J Cancer; 1992; 28A(6-7):1099-105. PubMed ID: 1352696
[TBL] [Abstract][Full Text] [Related]
36. A new procedure for the preparation of liposomal doxorubicin: biological activity in multidrug-resistant tumor cells.
Thierry AR; Rahman A; Dritschilo A
Cancer Chemother Pharmacol; 1994; 35(1):84-8. PubMed ID: 7987982
[TBL] [Abstract][Full Text] [Related]
37. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.
Wang Y; Eksborg S; Lewensohn R; Lindberg A; Liliemark E
Anticancer Drugs; 1999 Nov; 10(10):921-8. PubMed ID: 10630360
[TBL] [Abstract][Full Text] [Related]
38. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM.
Kimiya K; Naito S; Soejima T; Sakamoto N; Kotoh S; Kumazawa J; Tsuruo T
J Urol; 1992 Aug; 148(2 Pt 1):441-5. PubMed ID: 1353119
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells.
Fritzer M; Szekeres T; Szüts V; Jarayam HN; Goldenberg H
Biochem Pharmacol; 1996 Feb; 51(4):489-93. PubMed ID: 8619895
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.
Cuvier C; Roblot-Treupel L; Millot JM; Lizard G; Chevillard S; Manfait M; Couvreur P; Poupon MF
Biochem Pharmacol; 1992 Aug; 44(3):509-17. PubMed ID: 1354963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
